Omeros' (OMER) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Omeros (NASDAQ:OMER - Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $36.00 price objective on the biopharmaceutical company's stock.

A number of other research analysts also recently commented on OMER. HC Wainwright began coverage on shares of Omeros in a research note on Tuesday, June 10th. They set a "buy" rating and a $9.00 price objective for the company. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a report on Friday, May 16th. Finally, Wall Street Zen lowered Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Stock Performance

OMER stock traded up $0.11 during trading on Monday, reaching $3.20. 536,692 shares of the company were exchanged, compared to its average volume of 722,218. The stock's 50 day moving average price is $4.21 and its 200 day moving average price is $7.06. Omeros has a 52-week low of $2.95 and a 52-week high of $13.60. The company has a market cap of $187.56 million, a P/E ratio of -1.21 and a beta of 2.16.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). As a group, equities research analysts forecast that Omeros will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently made changes to their positions in OMER. Truvestments Capital LLC increased its holdings in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 1,972 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Omeros in the fourth quarter valued at about $46,000. Picton Mahoney Asset Management raised its holdings in shares of Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after buying an additional 4,404 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Omeros by 14,486.3% during the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 7,388 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.